Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States.
US guidelines recommend standard genotype at HIV diagnosis ("baseline genotype") to detect transmitted drug resistance (TDR) to NNRTIs, NRTIs, and PIs. With INSTI-based regimens now recommended as first-line ART, the clinical and economic value of baseline genotypes is uncertain. We used the CEPAC model to examine the clinical impact and cost-effectiveness of Baseline Genotype compared to No Baseline Genotype for people starting ART with dolutegravir (DTG) and an NRTI pair. For people with no TDR (83.8%), baseline genotype does not alter regimen selection. Among people with transmitted NRTI resistance (NRTI-R, 5.8%), baseline genotype guides NRTI pair selection and informs subsequent ART after adverse events (DTG AE, 14%). Among people with transmitted NNRTI resistance (NNRTI-R, 7.2%), baseline genotype influences care only for people with DTG AE who move to an NNRTI-based regimen. 48-week virologic suppression varied (40%-92%), depending on TDR. Costs included $320/genotype, $3,000/month for DTG-based and darunavir/ritonavir-based regimens, and $2,500/month for rilpivirine-based regimens. Compared to No Baseline Genotype, Baseline Genotype would result in <1 additional undiscounted quality-adjusted life day (QALD), cost $500 more per person, and would not be cost-effective (ICER, $420,000/quality-adjusted life year). In univariate sensitivity analysis, the clinical benefits of Baseline Genotype never exceeded 5 QALDs for all newly diagnosed people with HIV. Baseline Genotype was cost-effective at current TDR prevalence only under unlikely conditions, such as DTG-based regimens achieving ≤50% suppression of transmitted NRTI-R. With INSTI-based first-line regimens in the US, Baseline Genotype offers minimal clinical benefit and is not cost-effective.